Abstract
Targeting DNA repair proteins with small-molecule inhibitors became a proven anti-cancer strategy. Previously, we identified an inhibitor of a major protein of homologous recombination (HR) RAD51, named B02. B02 inhibited HR in human cells and sensitized them to chemotherapeutic drugs in vitro and in vivo. Here, using a medicinal chemistry approach, we aimed to improve the potency of B02. We identified the B02 analog, B02-isomer, which inhibits HR in human cells with significantly higher efficiency. We also show that B02-iso sensitizes triple-negative breast cancer MDA-MB-231 cells to the PARP inhibitor (PARPi) olaparib.
| Original language | English (US) |
|---|---|
| Article number | 920 |
| Journal | Genes |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2021 |
Keywords
- DNA repair
- Homologous recombination
- Small-molecule inhibitors
- Triple-negative breast cancer
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)
Fingerprint
Dive into the research topics of 'New rad51 inhibitors to target homologous recombination in human cells'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS